

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181 JAGSONPAL PHARMACEUTICALS LIMITED

Audited Financial Results for the Quarter ended 31.03.2015

	And the state of t		9			Rs. in lacs
	PART-I			0	40 Mantha	40 Months
	Particulars	3 months	3 months	3 months	12 Months	12 Months Ended
		ended	ended	ended	ended 31.03.2015	31.03.2014
		31.03.2015	31.12.2014	31.03.2014	Audited	Audited
-		Audited	Unaudited	Audited	Audited	Audited
1	Income from operations	000400	2040.00	2420.00	13815.09	14385.09
а	Net sales/Income from Operations (Net of excise duty)	3884.86	3242.86	3128.08	13015.09	14365.09
b	Other Operating Income					
	Total Income from operations (net)	3884.86	3242.86	3128.08	13815.09	14385.09
2	Expenses					*
а	Cost of materials consumed	1960.65	1567.32	1047.14	6383.36	5461.64
b	Purchases of stock-in-trade	42.59	50.18	565.48	649.48	1294.90
C.	Changes in inventories of finished goods, work	278.47	-48.08	-939.18	-164.55	-285.94
d.	Employee benefits expenses	816.96	744.79	1022.02	3211.33	3783.43
e.	Depreciation and amortisation expense	56.03	71.76	68.51	270.69	282.54
f.	Other expenses	636.83	742.01	1061.74	2862.86	3063.27
	Total expenses	3791.53	3127.98	2825.71	13213.17	13599.84
3	Profit from Operations before Other Income,					
E/	Finance Cost and Exceptional items (1-2)	93.33	114.88	302.37	601.92	785.25
4	Other Income	5.55	0.41	6.07	11.10	6.07
5	Profit from ordinary activities before finance cost and Exceptional items (3+4)	98.88	115.29	308.44	613.02	791.32
6	Finance Cost	105.69	112.01	183.16	445.85	538.19
7	Profit from ordinary activities after finance cost	-6.81	3.28	125.28	167.17	253.13
8	but before Exceptional Items (5-6) Exceptional Items			₹.		
9	Profit(+)/Loss(-) from Ordinary Activities before	-6.81	3.28	125.28	167.17	253.13
	tax (7+8)					
10	Tax expense	-13.60	0.66	3.08	50.06	41.06
11	Net Profit/Loss(-) from Ordinary Activities after	6.79	2.62	122.20	117.11	212.07
1 1	tax (9-10)	0.70	in. Via			
	tax (0-10)					
12	Extraordinary Items (net of tax expense Rs. lace	s)				
13	Net Profit(+)/Loss(-) for the period(11-12)	6.79	2.62	122.20	117.11	212.07
14	Share of profit/(Loss) of associates					
15	Minority interest					
16	Net Profit/(Loss) after taxes, minority interest	6.79	2.62	122.20	117.11	212.07
17		1309.90	1309.90	1309.90	1309.90	1309.90
	Reserves excluding Revaluation reserves as per					
	Balance sheet of pr. Accounting yr				7448.74	7298.31
19.	Earnings Per Share (before extraordinary items)			5-	The second	
a.	Basic (Rs.)	0.03	0.01	0.47	0.45	0.81
h	Diluted (Rs.)	0.03	0.01	0.47	0.45	0.81
b.	i Earnings Per Share (after extraordinary items)	0.03	0.01	9.11	2.10	
		0.03	0.01	0.47	0.45	0.81
a.	Basic (Rs.)	0.03	0.01	0.77	3.40	0.01

Factory: 20 K.M. Mathura Road, Post Office Amar Magar, Faridabad-121003 (India) Phone: 0091-95129-2275952, 2275953 Factory: Plot No. 14, 15, 16, 55, 56, 57, Sector 5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

0.03

Diluted (Rs.)

0.01

0.47

0.45

0.81

CIN No. L74899DLI978PLC009181



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

PART-II

Α	PARTICULARS OF SHAREHOLDING					
1	Public Shareholding					-
	- Number of shares	8962360	8962360	8962360	8962360	8962360
	- Percentage of Shareholding	30.83%	30.83%	34.21%	30.83%	34.21%
2	Promoter and promoter group shareholding					
Α	Pledged / encumbered					
_	Number of shares					
- 1	Percentage of shares (as a % of the total				E.	
	shareholding of Promoter and promoter group)					
-	Percentage of shares (as a % of the total					
	share capital of the Company)					
В	Non - encumbered	ï				
-	Number of shares	18121320	18121320	17235640	18121320	17235640
_	Percentage of shares (as a % of the total	100%	100%	100%	100%	100%
	shareholding of Promoter and promoter group)	×				
-	Percentage of shares (as a % of the total	69.17%	69,17%	. 65.79%	69.17%	65.79%
	share capital of the Company)					
В	INVESTOR COMPLAINTS					
	Pending at the beginning of the quarter	0	0	0		
	Received during the quarter	44	23	40		
	Disposed of during the quarter	44	23	40		
	Remaining unresolved at the end of the	0	0	0		
	-	0	0	0		

Notes

- 1. The Audited Financial Results for the Quarter ended 31.03.2015 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 29.05.2015
- 2. The figures for the quarter ended 31st March, 2015 represents the derived figures between the audited figures in respect of the year ended 31st March, 2015 and the unaudited published period to date figures upto 31st December, 2014 being the date of the end of the third quarter of the current year, which was subjected to a limited review.
- 3. In accordance with the companies Act, 2013 the company has revised the useful life of its fixed assets to comply with the useful life as mentioned under Schedule II of Companies Act, 2013. Based on transitional provision, given in Schedule II to the companies Act, 2013, the carrying value of assets whose useful lives are already exhausted amounting to Rs 385.76 lacs (net of deferred tax of Rs 64.76 lacs) has been adjusted with the opening balance of Reserve. Had there been no change in useful lives of fixed assets, the charge to the statement of profit and loss would have been lower by Rs 19.62 Lacs.
- 4. The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- 5. The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- 6. Previous year figures have been regrouped / rearranged wherever necessary.
- 7. The Board has recommended today, a final dividend of Rs 0.10 per share(2%) subject to approval of the shareholders at the ensuing Annual General Meeting.

By Order of the Board

For Jagsonpal Pharmaceuticals Limited

Place: New Delhi Date: 29.05.2014 Raipal Singh Kochhar Managing Director DIN No 00059492

Factory: 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone: 0091-95129-2275952, 2275953 Factory: Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

CIN No. L74899DLI978PLC009181

Statement of Assets and Liabilities

				0000.10	0010.10	ייים בייים בייים ומסוויים כי
				5358 46	5519 18	Sub-Total - Current liabilities
				706.15	176.79	(d) Short term provisions
				548.10	624.45	(c) Other current liabilities
.0	15422.00	TOTAL - ASSETS		508.45	786.89	(b) Trade payables
				3595.76	3931.05	(a) Short term borrowing
.30	9579.30	Sub-Total - Current assets				Current liabilities
.00	0.	(f) Other current assets				
.62	282.	(e) Short term loans and advance		408.39	360.26	Sub-total - Non-current liabilities
.61	1501.	(d) Cash and Cash equivalents		0.00	0.00	(d) Long term provisions
.87	4488.	(c) Trade receivables		0.00	0.00	(c) Other long term liabilities
.20	3306.	(b) Inventories		408.39	360.26	(b) Deferred tax liabilities (net)
		(a) Current investments		0.00		(a) Long term borrowings
		Current assets	2			Non-current liabilites
.70	5842.	Sub-total - Non-current assets		0.00	0.00	Minority interest
00	0.	(f) Other non-current assets				
.62	646.	(e) Long term loans and advance		0.00	0.00	Share application money pending allotment
.0	0.00	(d) Deferred tax assets (net)				
.05	0.	(c) Non-current investments		9858.87	9542.56	Sub-total - Shareholders' funds
.00	3.	(b) Goodwill		8548.97	8232.66	(b) Reserves and surplus
.03	5193.	(a) Fixed Assets		1309.90	1309.90	(a) Share Capital
		Non-current assets	ы			Shareholders' funds
015 31.03.201	31.03.2015			31.03.2014	31.03.2015	
at	As	ASSETS	œ	As at	As at	EQUITY AND LIABILITIES
				NS. III IQUS		
				De In lace		

For Jagasnpal Pharmacouticals fimited

TOTAL - EQUITY AND LIABILITIES

15422.00

15625.72

Director

P.P. THUKRAL & CO.

CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre, Babar Road, New Delhi - 110 001

Ph. (O): 23413486

E-mail: sureshsethi62@yahoo.com

AUDITORS' REPORT ON CORPORATE GOVERNANCE

To the members of Jagsonpal Pharmaceuticals Limited

We have examined the compliance of conditions of Corporate Governance by Jagsonpal Pharmaceuticals Limited for the year ended on 31st March, 2015 as stipulated in Clause 49 of the Listing Agreement of the said Company with the Stock Exchanges.

The compliance of conditions of Corporate Governance is the responsibility of the management. Our examination was imited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an Audit nor an expression of opinion on the financial statement of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied in all material aspect with the conditions of Corporate Governance as stipulated by the above mentioned Listing Agreement.

We state that no investor grievances are pending for a period exceeding one month against the Company as per the records maintained by the Company and presented to the Investors' Grievances Committee.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Place: New Delhi

Date: 29th May, 2015

For P.P. Thukral & Company
Chartered Accountants

FRN No 000632 N

resh Sethi Partner

M.No. 89318